Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm Pharmaceuticals's book value per share for the quarter that ended in Dec. 2025 was E£508.46.
During the past 12 months, Minapharm Pharmaceuticals's average Book Value Per Share Growth Rate was 45.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Minapharm Pharmaceuticals was 31.80% per year. The lowest was 28.30% per year. And the median was 30.05% per year.
Minapharm Pharmaceuticals (CAI:MIPH) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Minapharm Pharmaceuticals Book Value per Share Related Terms
Minapharm Pharmaceuticals Book Value per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals Book Value per Share Chart
CAI:MIPH vs ZTS, UTHR, VTRS: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of E£508.46 mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Book Value per Share of E£508.46 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Book Value per Share too high?
Minapharm Pharmaceuticals' current Book Value per Share is E£508.46. Overall, Minapharm Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Book Value per Share compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Book Value per Share of E£508.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Book Value per Share is E£508.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£372.18, compared to a current price of E£793.89 — trading 113.3% above its estimated fair value. The current Book Value per Share is E£508.46. Minapharm Pharmaceuticals' overall GF Score™ is 49/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Book Value per Share is E£508.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£793.89 is trading 113.3% above its estimated GF Value™ of E£372.18.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Book Value per Share: E£508.46
GF Value™: E£372.18 vs. price of E£793.89 (113.3% above fair value)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score
Get the complete analysis for CAI:MIPH
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
